Needham Maintains Buy on BioCryst Pharma, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Neutral 48.1%

Neg 0% Neu 48.1% Pos 0%

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the price target from $18 to $16.